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Introduction
Angiogenesis, or neovascularization, is strictly required for tumor expansion, with respect to both growth and metastasis (Carmeliet and Jain, 2000) . Tumor-induced angiogenesis is mediated by proangiogenic factors, including vascular endothelial growth factor A (VEGF-A), platelet-derived growth factor (PDGF), and fibroblast growth factor-1 (FGF-1) and -2 (FGF-2) (Nyberg et al., 2005) .
Several agents targeting the VEGF/VEGF receptor (VEGFR) pathway have demonstrated a survival advantage for patients with advanced cancer, either as monotherapy (sunitinib or sorafenib in renal cell carcinoma (Escudier et al., 2007; Motzer et al., 2007) and sorafenib in hepatocellular carcinoma [HCC] (Llovet et al., 2008b) ) or as part of a combination therapy regimen (bevacizumab in colorectal cancer (Hurwitz et al., 2008) and lung cancer (Hurwitz et al., 2008; Sandler et al., 2006) ). Responses to these therapies, however, are modest and transient, and significant toxicities may occur at therapeutic concentrations (Je et al., 2009 ).
The tyrosine kinase inhibitors (TKIs) comprise a relatively new group of anticancer drugs that has been developed as oral formulations and administered on a daily basis. The mechanism of action of TKIs, includes modulation of key pathways and mechanisms of angiogenesis and tumorigenesis such as VEGFR, ErB and PDGFR (Arora and Scholar, 2005) . TKIs compete with the ATP binding site of the catalytic domain of several oncogenic tyrosine kinases to inhibit transduction of extracellular signals to the cytoplasm (Arora and Scholar 2005) . However, TK involvement and activity may vary from tumor to tumor, resulting in differing responses to different TKIs. To date, most of the available pharmacokinetic (PK) information available is based on information obtained from in vitro experiments, animal studies, drug-drug interactions, and massThis article has not been copyedited and formatted. The final version may differ from this version. Absorption, distribution, metabolism, and excretion (ADME) studies are a crucial part of a drug's development program, particularly an anticancer drug, because plasma levels of anticancer agents are often associated with both activity and toxicity, creating a narrow therapeutic window (Beumer et al., 2006) . In particular, data are limited on the effects of mild, moderate, or severe renal or hepatic impairment on the PK of TKIs (van Erp et al., 2009) . ADME studies can help determine the likely impact of renal or hepatic impairment on the PK of a new agent.
Brivanib, a small-molecule TKI, is the first selective dual inhibitor of FGF and VEGF signaling (Bhide et al., 2006) and is formulated as an orally administered L-alanine ester prodrug, brivanib alaninate (Cai et al., 2008; Marathe et al., 2009) (Fig. 1) . Preclinical studies have demonstrated that dual inhibition of FGF and VEGF signaling by brivanib has strong antiangiogenic effects (Bhide et al., 2010; Huynh et al., 2008) , and potent direct effects on tumor cells across a range of tumor types, including breast (Bhide et al., 2010) , liver (Bhide et al., 2010; Huynh et al., 2008) , colon, and lung (Bhide et al., 2010; Cai et al., 2008) . Promising clinical activity has been seen with brivanib in a Phase II study in patients with advanced HCC in the first-and second-line settings (Raoul et al., 2009) . Brivanib is being investigated in a Phase III development program in HCC, and in combination with other anticancer agents for the treatment of several tumor types, including colorectal cancer.
Preclinical in vitro and in vivo PK studies in four animal species (mouse, rat, dog, and monkey) have demonstrated that brivanib alaninate is rapidly and efficiently converted to its active moiety, brivanib, and brivanib's clearance in humans is expected to be low to This article has not been copyedited and formatted. The final version may differ from this version. weeks since last dose of chemotherapy (6 weeks from last dose of nitrosoureas, mitomycin C, or liposomal doxorubicin). Patients were excluded from the study if they were women who were pregnant or breast-feeding, women of child-bearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period and for at least 3 months after the study, or sexually active fertile men who were unwilling or unable to use a barrier contraception or whose partners were women of child-bearing potential not using an adequate method of birth control from the time of enrollment and for 3 months after participation in the study.
Patients were also excluded if they had brain metastasis or signs and symptoms 10 Serial blood samples were collected for analyses of PK and TRA over a 10-day period at predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216 , and 240 h. All blood samples were collected into 3-ml tubes containing EDTA as the anticoagulant and 0.45 ml 3.14 M glycine buffer (to prevent the ex vivo conversion of brivanib alaninate to brivanib). Plasma was prepared from the blood samples by centrifuging at room temperature for 15 min at 1300 × g. The plasma samples were then stored at -20°C until analysis. Complete urinary and fecal output was collected at 24-h intervals over the 10-day period or until discharge and analyzed for
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Results
Patient Population. Seven patients were enrolled and provided written informed consent; two patients later withdrew consent and one no longer met the study inclusion criteria. Of the remaining four patients, two with non-small cell lung cancer, one with ovarian cancer, and one with renal cell carcinoma were treated in Part A and Part B of this study (Table 1 ). Three of the treated patients were male and one was female; the mean age was 65 years (range 51-79 years).
Pharmacokinetics. The mean plasma concentration-time profile of TRA and brivanib in plasma is shown in Fig. 3 . There were minimal differences in the plasma concentrationtime profile among patients. The median T max of brivanib was 1 h and the geometric mean C max was 6,146 ng/ml. The mean T 1/2 of brivanib was 13.8 h and the geometric mean CL/F was 14.7 l/h ( of the administered radioactivity was recovered in urine and feces, respectively, for a total recovery of 93.7% (Table 3) . After oral administration, brivanib alaninate was completely converted to the active moiety, brivanib. Brivanib alaninate was not detected in plasma. The predominant route of elimination of drug-related material was fecal. As 
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reported by Gong et al., brivanib represented 7.5% of the dose in feces (Gong et al., 2010) . Thus, the percentage of brivanib absorbed when administered as brivanib alaninate was at least 86% (93.7% total recovery-7.5%). Renal excretion of unchanged brivanib was minimal.
Safety. Brivanib was well tolerated. Fatigue was the most frequent AE that occurred in all four patients and the most frequent treatment-related AE occurring in three patients (75%). All four patients experienced gastrointestinal events, the most common being nausea, diarrhea, and constipation. There were no deaths, serious AEs, or discontinuations due to AEs in Part A. In Part B, one patient discontinued treatment due to a serious AE of grade 3 dysphagia, which was not related to treatment. All AEs in Part A and the majority of events in Part B were mild (grade 1 or 2) in severity. Grade 2 AEs included single events of fatigue, abdominal pain, dysphagia, back pain, cognitive disorder, and cachexia. No grade 4 events were reported, and one patient died due to disease progression, which was reported as a grade 5 serious AE.
Efficacy. During treatment in the study, which ranged from approximately 4 to 9 weeks, the best clinical response in one patient with non-small cell lung cancer (NSCLC) was stable disease and the other three patients with NSCLC, ovarian cancer, and renal cell carcinoma, had progressive disease.
Discussion
This study was carried out in tandem with a study by Gong et al. (Gong et al., 2010) to provide information on the routes of elimination of brivanib alaninate and its metabolites to anticipate any likely effects of renal or hepatic impairment on the disposition of brivanib alaninate.
Four patients with advanced/metastatic solid tumors received single oral doses of prodrug was not detected in plasma, demonstrating that the prodrug was efficiently converted to its active moiety. Brivanib was metabolized by multiple metabolic routes, as reported by Gong et al. (Gong et al., 2010) , and excreted primarily as metabolites in feces, with 81.54 % of total radioactivity recovered in feces and 7.5% as unchanged brivanib. Brivanib absorption was high (>86%) in patients with advanced cancer when administered orally as brivanib alaninate. Renal excretion of brivanib was minimal;
therefore, renal impairment is unlikely to affect brivanib exposure. Recovery of radioactivity was high (93.7%) and minimally variable among patients, suggesting similar elimination of this drug by the diverse population of patients with advanced cancer in this study. Biotransformation and metabolite identification analyses were conducted on plasma, urine, and fecal samples in a separate study using patient samples from the 18 study reported here (Gong et al., 2010) . Brivanib was found to be the major active circulating component in plasma samples collected before 12 h. Minor metabolites were detected in plasma but none are expected to be biologically active.
Results from the current study and that of Gong et al. (Gong et al., 2010) demonstrate that brivanib is extensively metabolized, with metabolites accounting for more than 90%
of the excreted radioactivity. In addition, Gong et al. reported that brivanib was primarily metabolized by multiple liver enzymes, including cytochrome P450 A12 (CYP1A2), CYP3A4, and multiple sulfotransferases (Gong et al., 2010) . It is anticipated that the involvement of multiple enzymes in the metabolism of brivanib would make brivanib less susceptible to drug-drug interactions compared with other agents such as sunitinib and sorafenib, which are metabolized primarily by CYP3A4 with additional glucuronidation by UDP glucuronyl transferase A19 in the case of sorafenib (Faivre et al., 2006; Kane et al., 2006; Miller et al., 2009) . As a result, concomitant treatment with CYP3A4 inhibitors and inducers must be avoided with these two agents. As brivanib is primarily metabolized in the liver, the effect of hepatic impairment on brivanib is currently being investigated in an ongoing PK study (clinicaltrials.gov identifier:NCT00437424). The T 1/2 of brivanib was 13.8 h in this study whereas the reported T 1/2 of sorafenib ranges from 41 to 86 h (Faivre et al., 2006) and that of sunitinib from 40 to 60 h (Hartmann et al., 2009 ). The shorter T 1/2 of brivanib compared with sorafenib and sunitinib therefore allows for once-daily dosing with limited accumulation in plasma upon multiple daily dosing.
Although this was not a trial to establish efficacy and the duration of treatment was short (4-9 weeks), the response to treatment was encouraging, with one of four patients achieving stable disease. These data correlate with and support the preliminary clinical activity observed with brivanib in an ongoing Phase II study of first-line brivanib (Llovet et al., 2008a; Raoul et al., 2009 ).
The safety profile of brivanib was manageable in this population with advanced cancer.
The most frequent AEs were fatigue (four [100%] patients) and gastrointestinal events (nausea, diarrhea, and constipation, each reported in two [50%] patients). Although hypertension has been reported with other agents in this class (Hartmann et al., 2009; Morabito et al., 2006) , there were no reported AEs of increased blood pressure among the four patients treated in this study, and no reported cases of hand-foot syndrome.
Brivanib alaninate represents a potential therapeutic advance over current VEGFdirected therapies through dual targeting of the FGF signaling pathway, which appears to play a role in the development of resistance to VEGF-targeted therapies and the VEGF signaling pathway. Thus, dual targeting of FGF and VEGF signaling pathways may provide prolonged clinical benefit to patients. In this study, brivanib was rapidly absorbed and extensively metabolized in humans after a single 800-mg oral dose, with the majority of drug-related radioactivity excreted in feces. Consistent with the results from other studies, brivanib was well tolerated and has a manageable safety profile in this group of patients with advanced cancer.
